Pulse Biosciences to Present at TD Cowen Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy PLSE?
Source: Newsfilter
- Conference Announcement: Pulse Biosciences is scheduled to present its innovative nPulse™ technology at the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, 2026, which is expected to garner significant attention from the healthcare industry.
- Technology Overview: The company's nPulse™ technology employs nanosecond pulsed field ablation (nsPFA™) energy to non-thermally clear cells while sparing adjacent noncellular tissue, showcasing its substantial potential in the medical field.
- Market Applications: Pulse Biosciences is actively pursuing the development of its nPulse technology for treating atrial fibrillation and in surgical soft tissue ablation, which could profoundly improve healthcare outcomes for patients and providers alike.
- Investor Information: The presentation will be available via live and recorded webcast on the company's investor website's
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLSE
Wall Street analysts forecast PLSE stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 22.400
Low
22.00
Averages
22.00
High
22.00
Current: 22.400
Low
22.00
Averages
22.00
High
22.00
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulse Biosciences Accelerates Cardiac Catheter Ablation System Development
- Clinical Study Results: Pulse Biosciences has decided to accelerate the development of its Pulse Cardiac Catheter Ablation System based on a European feasibility study that indicates its Nanosecond Pulsed Field Ablation technology offers a unique combination of speed, safety, and long-term efficacy in treating Atrial Fibrillation.
- Efficacy Data: The study revealed that at 12 months, 45 out of 47 patients (96%) achieved durable pulmonary vein isolation, significantly lower than the typical 20%-25% recurrence rate, highlighting the clinical advantages of this technology.
- R&D Investment Focus: Pulse Biosciences stated that the majority of its R&D and clinical investments will now be directed towards the upcoming pivotal IDE study and related regulatory submissions, aiming to expedite the product's market entry.
- Market Outlook: With advancements in the nPulse platform's clinical milestones, Pulse Biosciences plans to target CE Mark submission in 2026, further solidifying its market position in cardiac treatment.
See More
Pulse Biosciences Accelerates Development of Cardiac Catheter System
- Breakthrough Clinical Data: Pulse Biosciences' European feasibility study involving 150 patients demonstrated a 100% procedural success rate, with all 75 evaluable patients achieving acute Pulmonary Vein Isolation, indicating the potential to transform clinical practices in atrial fibrillation treatment.
- Significant Long-term Efficacy: Follow-up at 12 months revealed a 96% sustained success rate for Pulmonary Vein Isolation, significantly exceeding the traditional 20-25% recurrence rates, suggesting a strong market acceptance for this innovative treatment.
- Strategic Resource Realignment: The company is reallocating the majority of its R&D and clinical investments to focus on the nPulse Cardiac Catheter program, planning pivotal IDE studies in the U.S. and Europe, reflecting a strong commitment to the electrophysiology market and aiming for expedited product commercialization.
- Upcoming Milestones: Pulse Biosciences is set to present late-breaking clinical data on AFib treatment at the 2026 Heart Rhythm Conference, which is expected to further validate the efficacy and safety of its technology, potentially attracting significant investor and medical community interest.
See More
Pulse Biosciences Accelerates Development of Cardiac Catheter System
- Clinical Data Breakthrough: Pulse Biosciences' European feasibility study involving 150 patients demonstrated a 100% procedural success rate, with all 75 evaluable patients achieving acute Pulmonary Vein Isolation (PVI), indicating the potential to transform clinical practices in atrial fibrillation treatment.
- Significant Long-Term Efficacy: Follow-up at 12 months revealed a 96% sustained success rate for PVI, significantly exceeding the traditional 20-25% recurrence rates, thereby establishing the technology's leading position in the electrophysiology field.
- Strategic Resource Realignment: The company is reallocating the majority of its R&D and clinical investments to the upcoming pivotal IDE study for the nPulse Cardiac Catheter in the U.S. and Europe, aiming to accelerate market development and optimize capital allocation to seize high-value growth opportunities.
- Upcoming Milestones: Late-breaking clinical data on the nPulse Cardiac Catheter System will be presented at the Heart Rhythm 2026 conference, further validating its efficacy in treating atrial fibrillation and likely attracting increased investor interest.
See More
Pulse Biosciences Initiates Thyroid Cancer Study
- Patient Enrollment Begins: Pulse Biosciences has announced the first patient enrollments in the feasibility study of its nPulse Vybrance Percutaneous Electrode System for T1N0M0 papillary thyroid microcarcinoma, planning to enroll 30 patients across two study sites, marking a significant advancement in the field of bioelectric medicine.
- Significant Technical Advantages: The system employs nanosecond Pulsed Field Ablation (nsPFA) technology, enabling precise, non-thermal removal of cellular tissue without damaging non-cellular structures, thus providing a new potential for thyroid cancer treatment while enhancing safety and efficacy.
- FDA Certification Support: The nPulse Vybrance system has received FDA 510(k) clearance for soft-tissue ablation and is currently being evaluated under an Investigational Device Exemption (IDE) specifically for thyroid cancer applications, indicating its potential in the medical device market.
- Strong Market Performance: PLSE stock has traded between $12.56 and $26.30 over the past year, closing at $21.30 on Thursday with a 6.45% increase, reflecting investor optimism regarding the company's new technology and research progress.
See More
Pulse Biosciences Initiates Thyroid Cancer Clinical Trial
- First Patient Enrollment: Pulse Biosciences successfully enrolled and treated its first patient at two medical centers in Florida and Texas, marking a significant milestone for its nPulse™ Vybrance™ system in treating T1N0M0 papillary thyroid microcarcinoma, which may provide new treatment options for low-risk thyroid cancer patients.
- Multicenter Study Design: The multicenter prospective feasibility study plans to enroll 30 patients to evaluate the safety and effectiveness of the nPulse™ system in treating tumors smaller than 1.5 cm, and if successful, it could change the current treatment standards.
- Significant Technical Advantages: The nPulse™ system utilizes nanosecond pulsed field ablation technology to precisely remove cellular tissue without damaging surrounding noncellular structures, offering a minimally invasive and nonthermal treatment option that may reduce the need for surgery.
- Importance of Strategic Collaboration: Collaborating with leading institutions like UT MD Anderson demonstrates the company's commitment to advancing medical innovation, with the potential to improve patient outcomes and enhance the precision of clinical treatments through rigorous data generation.
See More
Pulse Biosciences Reports Q4 2025 Earnings Beat Despite Share Sale Agreement
- Earnings Beat: Pulse Biosciences reported a Q4 2025 non-GAAP net loss of $0.26 per share on revenues of $264K, exceeding Street forecasts by $0.05 and $10K respectively, although the overall performance remains weak.
- Equity Sale Agreement: The company has entered into an agreement with TD Securities to sell up to approximately $60 million worth of common stock, with TD acting as the sales agent and earning a commission of up to 3%, aimed at bolstering the company's liquidity.
- Liquidity Decline: As of December 31, Pulse's cash and cash equivalents dropped about 32% year-over-year to $80.7 million, indicating pressure on the company's financial management that could impact future operational capabilities.
- Market Reaction: Despite the earnings beat, Pulse's stock traded lower following the announcement, reflecting investor concerns over the company's liquidity situation, which may affect its future financing capabilities and market confidence.
See More
Pulse Biosciences Accelerates Cardiac Catheter Ablation System Development
- Clinical Study Results: Pulse Biosciences has decided to accelerate the development of its Pulse Cardiac Catheter Ablation System based on a European feasibility study that indicates its Nanosecond Pulsed Field Ablation technology offers a unique combination of speed, safety, and long-term efficacy in treating Atrial Fibrillation.
- Efficacy Data: The study revealed that at 12 months, 45 out of 47 patients (96%) achieved durable pulmonary vein isolation, significantly lower than the typical 20%-25% recurrence rate, highlighting the clinical advantages of this technology.
- R&D Investment Focus: Pulse Biosciences stated that the majority of its R&D and clinical investments will now be directed towards the upcoming pivotal IDE study and related regulatory submissions, aiming to expedite the product's market entry.
- Market Outlook: With advancements in the nPulse platform's clinical milestones, Pulse Biosciences plans to target CE Mark submission in 2026, further solidifying its market position in cardiac treatment.
See More
Pulse Biosciences Accelerates Development of Cardiac Catheter System
- Breakthrough Clinical Data: Pulse Biosciences' European feasibility study involving 150 patients demonstrated a 100% procedural success rate, with all 75 evaluable patients achieving acute Pulmonary Vein Isolation, indicating the potential to transform clinical practices in atrial fibrillation treatment.
- Significant Long-term Efficacy: Follow-up at 12 months revealed a 96% sustained success rate for Pulmonary Vein Isolation, significantly exceeding the traditional 20-25% recurrence rates, suggesting a strong market acceptance for this innovative treatment.
- Strategic Resource Realignment: The company is reallocating the majority of its R&D and clinical investments to focus on the nPulse Cardiac Catheter program, planning pivotal IDE studies in the U.S. and Europe, reflecting a strong commitment to the electrophysiology market and aiming for expedited product commercialization.
- Upcoming Milestones: Pulse Biosciences is set to present late-breaking clinical data on AFib treatment at the 2026 Heart Rhythm Conference, which is expected to further validate the efficacy and safety of its technology, potentially attracting significant investor and medical community interest.
See More
Pulse Biosciences Accelerates Development of Cardiac Catheter System
- Clinical Data Breakthrough: Pulse Biosciences' European feasibility study involving 150 patients demonstrated a 100% procedural success rate, with all 75 evaluable patients achieving acute Pulmonary Vein Isolation (PVI), indicating the potential to transform clinical practices in atrial fibrillation treatment.
- Significant Long-Term Efficacy: Follow-up at 12 months revealed a 96% sustained success rate for PVI, significantly exceeding the traditional 20-25% recurrence rates, thereby establishing the technology's leading position in the electrophysiology field.
- Strategic Resource Realignment: The company is reallocating the majority of its R&D and clinical investments to the upcoming pivotal IDE study for the nPulse Cardiac Catheter in the U.S. and Europe, aiming to accelerate market development and optimize capital allocation to seize high-value growth opportunities.
- Upcoming Milestones: Late-breaking clinical data on the nPulse Cardiac Catheter System will be presented at the Heart Rhythm 2026 conference, further validating its efficacy in treating atrial fibrillation and likely attracting increased investor interest.
See More
Pulse Biosciences Initiates Thyroid Cancer Study
- Patient Enrollment Begins: Pulse Biosciences has announced the first patient enrollments in the feasibility study of its nPulse Vybrance Percutaneous Electrode System for T1N0M0 papillary thyroid microcarcinoma, planning to enroll 30 patients across two study sites, marking a significant advancement in the field of bioelectric medicine.
- Significant Technical Advantages: The system employs nanosecond Pulsed Field Ablation (nsPFA) technology, enabling precise, non-thermal removal of cellular tissue without damaging non-cellular structures, thus providing a new potential for thyroid cancer treatment while enhancing safety and efficacy.
- FDA Certification Support: The nPulse Vybrance system has received FDA 510(k) clearance for soft-tissue ablation and is currently being evaluated under an Investigational Device Exemption (IDE) specifically for thyroid cancer applications, indicating its potential in the medical device market.
- Strong Market Performance: PLSE stock has traded between $12.56 and $26.30 over the past year, closing at $21.30 on Thursday with a 6.45% increase, reflecting investor optimism regarding the company's new technology and research progress.
See More
Pulse Biosciences Initiates Thyroid Cancer Clinical Trial
- First Patient Enrollment: Pulse Biosciences successfully enrolled and treated its first patient at two medical centers in Florida and Texas, marking a significant milestone for its nPulse™ Vybrance™ system in treating T1N0M0 papillary thyroid microcarcinoma, which may provide new treatment options for low-risk thyroid cancer patients.
- Multicenter Study Design: The multicenter prospective feasibility study plans to enroll 30 patients to evaluate the safety and effectiveness of the nPulse™ system in treating tumors smaller than 1.5 cm, and if successful, it could change the current treatment standards.
- Significant Technical Advantages: The nPulse™ system utilizes nanosecond pulsed field ablation technology to precisely remove cellular tissue without damaging surrounding noncellular structures, offering a minimally invasive and nonthermal treatment option that may reduce the need for surgery.
- Importance of Strategic Collaboration: Collaborating with leading institutions like UT MD Anderson demonstrates the company's commitment to advancing medical innovation, with the potential to improve patient outcomes and enhance the precision of clinical treatments through rigorous data generation.
See More
Pulse Biosciences Reports Q4 2025 Earnings Beat Despite Share Sale Agreement
- Earnings Beat: Pulse Biosciences reported a Q4 2025 non-GAAP net loss of $0.26 per share on revenues of $264K, exceeding Street forecasts by $0.05 and $10K respectively, although the overall performance remains weak.
- Equity Sale Agreement: The company has entered into an agreement with TD Securities to sell up to approximately $60 million worth of common stock, with TD acting as the sales agent and earning a commission of up to 3%, aimed at bolstering the company's liquidity.
- Liquidity Decline: As of December 31, Pulse's cash and cash equivalents dropped about 32% year-over-year to $80.7 million, indicating pressure on the company's financial management that could impact future operational capabilities.
- Market Reaction: Despite the earnings beat, Pulse's stock traded lower following the announcement, reflecting investor concerns over the company's liquidity situation, which may affect its future financing capabilities and market confidence.
See More
